Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes-Reference-Cited by-同舟云学术

Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes

Published:2019-12-14 Issue:3 Volume:22 Page:393-403
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Gastaldelli Amalia¹^ORCID,Repetto Enrico²,Guja Cristian³^ORCID,Hardy Elise⁴,Han Jenny⁵,Jabbour Serge A.⁶^ORCID,Ferrannini Ele¹^ORCID

Affiliation:

1. CNR Institute of Clinical Physiology Pisa Italy

2. Global Medical CVRM, BioPharmaceuticals Medical, AstraZeneca Gaithersburg Maryland United States

3. Department of Diabetes, Nutrition and Metabolic DiseasesCarol Davila University of Medicine and Pharmacy Bucharest Romania

4. Late CVRM, BioPharmaceuticals R&D Gaithersburg Maryland United States

5. Pharmapace Inc., San Diego California United States

6. Division of Endocrinology, Diabetes and Metabolic DiseasesSidney Kimmel Medical College of Thomas Jefferson University Philadelphia Pennsylvania United States

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13907

Reference35 articles.

1. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels

2. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

3. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases

4. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

5. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2019

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes as a risk factor for MASH progression;Diabetes Research and Clinical Practice;2024-11

2. Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors;Advances in Medical Sciences;2024-09

3. Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism;Diabetes & Metabolism Journal;2024-05-31

4. Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction‐associated steatotic liver disease: A retrospective nationwide claims database study in Japan;Diabetes, Obesity and Metabolism;2024-05-06

5. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial;PLOS ONE;2024-05-03